Thanks for your 8-K, jmkobers - LOL

From Twitter - that volume says the last shares of the shelf offering just got sold.

Comments?

Last week, #Revance presented findings from a hyaluronic acid filler study at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS).
19 June Twitter Post

https://twitter.com/revance/status/1406304485413036032/photo/1

Friday, June 11

Sponsored By: Revance Aesthetics

Jackie Yee, MD

Beauty is dynamic, your filler should be too. Revance Aesthetics cordially invites you to join our esteemed faculty, Dr. Jackie Yee, for an engaging program including an injection demonstration with the RHA® Collection.

https://www.vegascosmeticsurgery.info/en/program/sponsored-workshops.html

Can't find any additional, detailed info re: study -

An oldie but goodie 3+ years ago, HOWEVER, quite relevant NOW!!

Revance Therapeutics CEO: Challenging Allergan | Mad Money | CNBC
2,634 views - Apr 19, 2018

Former CEO, Dan Browne, speaks to Cramer -

RVNC/Revance Therapeutics Inc - Short Interest Ownership

as of 1 June 2021 -

Short Owners....21

This page shows institutions, funds, and major shareholders that have reported short positions in their last reporting period. We consider put option positions to be short positions and include all institutions that have disclosed put options here. Green rows indicate new positions. Red rows indicate closed positions.

https://fintel.io/sosh/us/rvnc?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=sosh

RVNC SHORTS getting squeezed -

RVNC SHORTS getting squeezed -

Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection
Wed, May 26, 2021, 8:00 AM

RVNC

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the FDA plans to initiate its pre-approval inspection of the company’s manufacturing facility for DaxibotulinumtoxinA for Injection by the end of June 2021.

In November 2020, Revance received notification from the FDA that the Agency was deferring a decision on the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines because the required pre-approval inspection of the company’s manufacturing facility could not be completed due to travel restrictions associated with the COVID-19 pandemic.

Revance price target lowered to $36 from $37 at Mizuho. RVNC Mizuho analyst Vamil Divan lowered the firm's price target on Revance to $36 from $37 and keeps a Buy rating on the shares post the "strong" Q1 results.

Read more at:
https://thefly.com/n.php?id=3301519

Another positive - all RVNC directors, etc. acquired & HELD. Just the opposite of my Momenta Pharma where Craig, Young, Tony Manning et al disposed of their grants before the ink dried! Matter-of-fact, Tony "my hero" sold all his shares post haste thinking that the J&J buyout was kaput. LOL

RVNC -
1. SEC Form 4: Gangolli Julian S was granted 4,013 units of Common Stock, increasing direct ownership by 24% to 20,513 units
quantisnow.com/insight/7189...
2. SEC Form 4: Kolaja Carey OConnor was granted 674 units of Common Stock, increasing direct ownership by 11% to 6,968 units
quantisnow.com/insight/7189...
3. SEC Form 4: Nolet Chris was granted 4,013 units of Common Stock, increasing direct ownership by 27% to 19,013 units
quantisnow.com/insight/7189...
4. SEC Form 4: Russell Angus C. was granted 4,013 units of Common Stock, increasing direct ownership by 24% to 20,513 units
quantisnow.com/insight/7189...
5. SEC Form 4: Vickers Philip J. was granted 4,013 units of Common Stock, increasing direct ownership by 20% to 23,663 units
quantisnow.com/insight/7189...
6. SEC Form 4: Ware Olivia C was granted 674 units of Common Stock, increasing direct ownership by 11% to 7,082 units
quantisnow.com/insight/7189...

+ others HELD.

A 2nd positive news release today. Is approval next?

Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts
April 27, 2021

NASHVILLE, Tenn.--(BUSINESS WIRE)--Apr. 27, 2021-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an upcoming presentation at The American Society for Aesthetic Plastic Surgery (ASAPS) Aesthetic Meeting 2021, being held at The Miami Beach Convention Center in Miami Beach, FL from April 29 – May 3, 2021. The video presentation will include data from a subgroup analysis from the Phase 3 SAKURA clinical program demonstrating the efficacy, duration, and safety of DaxibotulinumtoxinA for Injection in adult females across multiple age cohorts following the treatment of glabellar lines.

DaxibotulinumtoxinA for Injection is a novel botulinum toxin type A for which Revance is currently seeking FDA approval for the treatment of glabellar lines (GL). It is generally accepted that as age increases, the efficacy of botulinum toxin decreases. This has been demonstrated in multiple studies with current aesthetic botulinum toxin products. The subgroup analysis from the Phase 3 SAKURA clinical program for glabellar lines (GL), which is the largest program for GL with over 3,000 subjects, examined the effects of DaxibotulinumtoxinA for Injection on GL among female subjects ages: 18-45, >45-55, and >55. A further analysis was performed on female subjects <65 and ≥65 years. The data from the analysis showed that DaxibotulinumtoxinA for Injection was safe, effective and delivered a median time to loss of none or mild of at least 24 weeks across all female age groups.

“We look forward to sharing the positive results from our Phase 3 SAKURA program at this year’s Aesthetic Meeting,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The data demonstrates DaxibotulinumtoxinA for Injection’s 24-week duration independent of age in women, in addition to its positive efficacy and safety endpoints in each subgroup analysed.”

The abstracts are available online via the ASAPS website at surgery.org.

Video Presentation:

Title: DaxibotulinumtoxinA for Injection Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program (SAKURA)
Authors and Affiliations: Glynis Ablon, Ava Shamban, Susan Weinkle, Jessica Brown, Yan Liu, Ablon Skin Institute, Manhattan Beach, CA; Ava MD, Santa Monica & Beverly Hills, CA; Susan H. Weinkle, MD, Bradenton, FL; Revance Therapeutics, Newark, CA

https://investors.revance.com/news-releases/news-release-details/revance-showcase-clinical-findings-aesthetic-meeting-2021

A 2nd positive news release today. Is approval next?

Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts
April 27, 2021

NASHVILLE, Tenn.--(BUSINESS WIRE)--Apr. 27, 2021-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an upcoming presentation at The American Society for Aesthetic Plastic Surgery (ASAPS) Aesthetic Meeting 2021, being held at The Miami Beach Convention Center in Miami Beach, FL from April 29 – May 3, 2021. The video presentation will include data from a subgroup analysis from the Phase 3 SAKURA clinical program demonstrating the efficacy, duration, and safety of DaxibotulinumtoxinA for Injection in adult females across multiple age cohorts following the treatment of glabellar lines.

DaxibotulinumtoxinA for Injection is a novel botulinum toxin type A for which Revance is currently seeking FDA approval for the treatment of glabellar lines (GL). It is generally accepted that as age increases, the efficacy of botulinum toxin decreases. This has been demonstrated in multiple studies with current aesthetic botulinum toxin products. The subgroup analysis from the Phase 3 SAKURA clinical program for glabellar lines (GL), which is the largest program for GL with over 3,000 subjects, examined the effects of DaxibotulinumtoxinA for Injection on GL among female subjects ages: 18-45, >45-55, and >55. A further analysis was performed on female subjects <65 and ≥65 years. The data from the analysis showed that DaxibotulinumtoxinA for Injection was safe, effective and delivered a median time to loss of none or mild of at least 24 weeks across all female age groups.

“We look forward to sharing the positive results from our Phase 3 SAKURA program at this year’s Aesthetic Meeting,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The data demonstrates DaxibotulinumtoxinA for Injection’s 24-week duration independent of age in women, in addition to its positive efficacy and safety endpoints in each subgroup analysed.”

The abstracts are available online via the ASAPS website at surgery.org.

Video Presentation:

Title: DaxibotulinumtoxinA for Injection Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program (SAKURA)
Authors and Affiliations: Glynis Ablon, Ava Shamban, Susan Weinkle, Jessica Brown, Yan Liu, Ablon Skin Institute, Manhattan Beach, CA; Ava MD, Santa Monica & Beverly Hills, CA; Susan H. Weinkle, MD, Bradenton, FL; Revance Therapeutics, Newark, CA

https://investors.revance.com/news-releases/news-release-details/revance-showcase-clinical-findings-aesthetic-meeting-2021

Revance says 1st patient enrolled for DaxibotulinumtoxinA study by Fosun Pharma 08:15 RVNC Revance Therapeutic announced that Shanghai Fosun Pharmaceutical Industrial Development, Fosun Pharma Industrial, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical has initiated Phase 3 trials of DaxibotulinumtoxinA for Injection in China, for the treatment of glabellar lines and cervical dystonia. Both trials enrolled and dosed their first patients in April. China is a fast-growing market for neuromodulators, with an estimated aesthetics and therapeutics opportunity of $318 million in 2021 that is projected to increase to $762 million by 2027, 15.7% CAGR. "The initiation of Phase 3 clinical trials for the treatment of glabellar lines and cervical dystonia marks an important advancement in our international expansion efforts and partnership with Fosun Pharma," said Mark J. Foley, President and Chief Executive Officer at Revance. "Fosun Pharma is a leading pharmaceutical and healthcare company in China and we look forward to continuing our collaboration with them in order to bring our next-generation product to the second largest neuromodulator market in the world." Revance entered into a license agreement with Fosun Pharma Industrial in 2018, whereby Fosun Pharma Industrial received exclusive rights to develop....

Read more at:
https://thefly.com/n.php?id=3290105

Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021

Fri, April 23, 2021, 8:00 AM

RVNC

-New DaxibotulinumtoxinA for Injection results from the SAKURA Phase 3 program will be presented, as well as two additional ePoster presentations-

Additional ePoster presentation highlighting findings from a study evaluating hyaluronic acid (HA) filler manufacturing technologies on HA chain degradation will be shared-

Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it will present four ePoster abstracts at the virtual American Academy of Dermatology (AAD VMX) meeting, April 23-25, 2021, including new data from the SAKURA Phase 3 clinical program for DaxibotulinumtoxinA for Injection, the company’s investigational, next-generation neuromodulator. The company will showcase new results on the elimination of glabellar lines following treatment with DaxibotulinumtoxinA for Injection, made evident through a novel approach visualizing the entire distribution of glabellar line severity ratings in the depiction of efficacy.

A second ePoster will highlight data from a subgroup analysis on the efficacy, duration and safety of DaxibotulinumtoxinA for Injection among adult female subjects across multiple age cohorts from the SAKURA Phase 3 program, and a third ePoster will include results from an evaluation of the progressive effects on static/resting glabellar lines with the repeated treatment of DaxibotulinumtoxinA for Injection. A fourth ePoster will highlight results from a study evaluating the impact of hyaluronic acid (HA) filler manufacturing technologies on HA chain degradation.

"We look forward to sharing new data from our SAKURA Phase 3 program with the aesthetic community at AAD VMX, as well as highlighting study results of our hyaluronic acid fillers manufacturing technology," said Roman Rubio, Senior Vice President of Clinical Development at Revance. "These data continue to underscore the innovation that drives Revance’s aesthetics portfolio, including our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, and the RHA® Collection, which was launched in September 2020."

The abstracts are available online via the AAD VMX website at www.aad.org. Attendees can access all of the sessions on-demand through July 12, 2021.

Abstracts to be presented at AAD:

Title: Visualizing the Elimination of Glabellar Lines Following Treatment with DaxibotulinumtoxinA for Injection (DAXI)
Authors and Affiliations: Shannon Humphrey, Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada, Sabrina Fabi, Cosmetic Laser Dermatology, San Diego, CA, USA, Derek Jones, Skin Care and Laser Physicians of Beverly Hills, Beverly Hills, CA, USA, Todd Gross, Yan Liu, Roman Rubio, Revance Therapeutics, Inc., Newark, CA, USA

Title: DaxibotulinumtoxinA for Injection (DAXI)–treated Subjects Show Progressive Improvement in Static Glabellar Lines With Repeated Treatment
Authors and Affiliations: Richard Glogau, Department of Dermatology, University of California at San Francisco, San Francisco, CA, USA, Theda Kontis, Johns Hopkins Medical Institutions, Baltimore, MD, USA, Yan Liu, Conor J Gallagher, Revance Therapeutics, Inc., Newark, CA, USA

Title: DaxibotulinumtoxinA for Injection (DAXI) Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program
Authors and Affiliations: Glynis Ablon, Ablon Skin Institute, Manhattan Beach, CA, Ava Shamban, Ava MD, Santa Monica & Beverly Hills, CA, Susan Weinkle, Susan H. Weinkle, MD, Bradenton, FL, Jessica Brown, Yan Liu, Revance Therapeutics, Inc., Newark, CA

Title: Evaluation of the Impact of Hyaluronic Acid (HA) Filler Manufacturing Technologies on HA Chain Degradation
Authors and Affiliations: Jay Mashburn, Revance Therapeutics, Inc., Newark, CA, Jimmy Faivre, François Bourdon, Teoxane, Geneva, Switzerland

https://investors.revance.com/news-releases/news-release-details/revance-present-data-daxibotulinumtoxina-injection-and

Revance Therapeutic (RVNC) PT Raised to $37 at Mizuho Securities
April 23, 2021 6:46 AM EDT
Mizuho Securities analyst Difei Yang ...

This is a premium only article.

With the recent success of our therapeutic clinical trial program, Revance has a transformational year ahead of us.

We are laying the foundation for our therapeutics franchise, and advancing our commercial strategy and launch plans.

As we advance our commercial planning for our therapeutics franchise, we are pleased to welcome Angela Willis to #Revance as our Vice President, Market Access. Angela brings over 20 years of experience in #biotech and has successfully developed market access capabilities for the launch of multiple commercial assets, including neurology and migraine products. Angela will be an instrumental leader as we prepare our therapeutics launch strategy. #DaringToMakeADifference #RevanceTherapeutics #RevanceAesthetics

Dustin S. Sjuts, Chief Commercial Officer
Facebbok & Twitter - April 21

Revance Therapeutics (NASDAQ:RVNC)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a report released on Wednesday [April 14], AnalystRatings.com reports. They currently have a $45.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 61.93% from the company’s previous close.

https://www.americanbankingnews.com/2021/04/14/needham-company-llc-reiterates-buy-rating-for-revance-therapeutics-nasdaqrvnc.html

OPUL is under trademark application by Revance Therapeutics, Inc.

Mark For: OPUL trademark registration is intended to cover the categories of providing online business information for healthcare professionals and medical aesthetics practitioners about practice management and administrative support related to facial and medical aesthetics products, and inventory management for facial and medical aesthetics products; administration of a customer loyalty program which provides incentives, rebates and rewards for frequent purchases of facial and medical aesthetics products.

https://uspto.report/TM/90619132 #OPUL

Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting

NASHVILLE, Tenn.--(BUSINESS WIRE)--Apr. 1, 2021-- Revance Therapeutics (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ePoster at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting taking place from April 17-22, 2021. Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.

“We’re pleased to present the efficacy and safety findings from the ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection at this year’s 2021 AAN Virtual Meeting, specifically, the median duration of effect of up to 24 weeks, as determined by time to loss of 80% peak treatment benefit, suggested that DaxibotulinumtoxinA for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually, while being generally safe and well tolerated,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The findings being presented are part of a growing body of clinical evidence that supports DaxibotulinumtoxinA for Injection’s differentiated performance profile and underscores the potential of our therapeutics pipeline for the treatment of muscle movement and pain disorders for patients who suffer from these debilitating conditions.”

The abstracts are available online via the AAN website at www.aan.com.

ePoster Presentation:

Title: A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia
Authors and Affiliations: Joseph Jankovic, Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX; Cynthia Comella, Rush University Medical Center, Chicago, IL; Robert A. Hauser, Director of the University of South Florida Parkinson’s Disease and Movement Disorders Center, Tampa, FL; Atul T. Patel, Kansas City Bone & Joint Clinic, Overland Park, KS; Todd M. Gross, Roman G. Rubio, Domenico Vitarella, Revance Therapeutics, Newark, CA
ASPEN Phase 3 Clinical Program in Cervical Dystonia

In 2017, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for DaxibotulinumtoxinA for Injection to treat cervical dystonia, which provides certain developmental and financial benefits to trial sponsors.

The company’s ASPEN Phase 3 clinical program consists of two trials to evaluate the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults: 1) ASPEN-1, a randomized, double-blind, placebo-controlled, parallel group trial and 2) ASPEN-OLS, an open-label, long-term safety trial.

Randomized Trial (ASPEN-1): Patients were randomized to a single treatment of either 125 Unit or 250 Unit dose of DaxibotulinumtoxinA for Injection, or placebo. Post-treatment, patients are followed for a maximum of 36 weeks. The primary efficacy endpoint of the trial was the mean change from baseline in the TWSTRS Total Score at the average of Weeks 4 and 6. Key secondary endpoints include the duration of treatment effect, measurement of treatment response on the Clinical and Patient Global Impression of Change assessments, and adverse events. Further, the trial featured exploratory efficacy assessments including the Cervical Dystonia Impact Profile (CDIP-58), a disease-specific, patient-rated questionnaire that measures quality of life.

Open-Label Study (ASPEN-OLS): Patients receive up to four sequential treatment cycles of DaxibotulinumtoxinA for Injection over the 52-week observation period. Primary endpoints of the trial are safety and immunogenicity after multiple cycles of treatment with DaxibotulinumtoxinA for Injection. Key secondary endpoints are the change from baseline in TWSTRS Total Score and the duration of treatment effect, as well as overall treatment response based on the Clinical and Patient Global Impression of Change. The ASPEN-OLS trial is fully enrolled with a total of 354 patients at sites located in the United States, Canada, and Europe.

Additional information about the ASPEN Phase 3 program is available at www.clinicaltrials.gov.

https://investors.revance.com/news-releases/news-release-details/revance-showcase-phase-3-results-evaluating-daxibotulinumtoxina

Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting
April 01, 2021
PDF Version
NASHVILLE, Tenn.--(BUSINESS WIRE)--Apr. 1, 2021-- Revance Therapeutics (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ePoster at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting taking place from April 17-22, 2021. Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.

“We’re pleased to present the efficacy and safety findings from the ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection at this year’s 2021 AAN Virtual Meeting, specifically, the median duration of effect of up to 24 weeks, as determined by time to loss of 80% peak treatment benefit, suggested that DaxibotulinumtoxinA for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually, while being generally safe and well tolerated,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The findings being presented are part of a growing body of clinical evidence that supports DaxibotulinumtoxinA for Injection’s differentiated performance profile and underscores the potential of our therapeutics pipeline for the treatment of muscle movement and pain disorders for patients who suffer from these debilitating conditions.”

The abstracts are available online via the AAN website at www.aan.com.

ePoster Presentation:

Title: A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia
Authors and Affiliations: Joseph Jankovic, Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX; Cynthia Comella, Rush University Medical Center, Chicago, IL; Robert A. Hauser, Director of the University of South Florida Parkinson’s Disease and Movement Disorders Center, Tampa, FL; Atul T. Patel, Kansas City Bone & Joint Clinic, Overland Park, KS; Todd M. Gross, Roman G. Rubio, Domenico Vitarella, Revance Therapeutics, Newark, CA
ASPEN Phase 3 Clinical Program in Cervical Dystonia

In 2017, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for DaxibotulinumtoxinA for Injection to treat cervical dystonia, which provides certain developmental and financial benefits to trial sponsors.

The company’s ASPEN Phase 3 clinical program consists of two trials to evaluate the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults: 1) ASPEN-1, a randomized, double-blind, placebo-controlled, parallel group trial and 2) ASPEN-OLS, an open-label, long-term safety trial.

Randomized Trial (ASPEN-1): Patients were randomized to a single treatment of either 125 Unit or 250 Unit dose of DaxibotulinumtoxinA for Injection, or placebo. Post-treatment, patients are followed for a maximum of 36 weeks. The primary efficacy endpoint of the trial was the mean change from baseline in the TWSTRS Total Score at the average of Weeks 4 and 6. Key secondary endpoints include the duration of treatment effect, measurement of treatment response on the Clinical and Patient Global Impression of Change assessments, and adverse events. Further, the trial featured exploratory efficacy assessments including the Cervical Dystonia Impact Profile (CDIP-58), a disease-specific, patient-rated questionnaire that measures quality of life.

Open-Label Study (ASPEN-OLS): Patients receive up to four sequential treatment cycles of DaxibotulinumtoxinA for Injection over the 52-week observation period. Primary endpoints of the trial are safety and immunogenicity after multiple cycles of treatment with DaxibotulinumtoxinA for Injection. Key secondary endpoints are the change from baseline in TWSTRS Total Score and the duration of treatment effect, as well as overall treatment response based on the Clinical and Patient Global Impression of Change. The ASPEN-OLS trial is fully enrolled with a total of 354 patients at sites located in the United States, Canada, and Europe.

Additional information about the ASPEN Phase 3 program is available at www.clinicaltrials.gov.

https://investors.revance.com/news-releases/news-release-details/revance-showcase-phase-3-results-evaluating-daxibotulinumtoxina

Say what??

They're leaving Microsoft & Google to come to Revance!

What about Apple, Tesla & the FLO Foundation?

Sr. Data Engineer

Excerpts:

Description -

Our technology puts them back where they should be—at the forefront of their business decisions. And we’re doing it by attracting top-tier talent, with a rapidly growing team comprised of tech industry experts from Microsoft, Google, and beyond. If you’re ready to build digital products that have the potential to transform an industry long overdue for change, we’re ready to meet you.

https://www.revance.com/careers/job-listings/?p=job%2FoRrwdfwL

New Career Post - Approval near term. Inspection completed?

Sr. Product Manager
Commercial, Marketing and Communications Irvine, California

Apply
Description
Position Summary

Excerpts:

Revance is preparing to launch a first-in-class challenger brand to the botulinum therapeutic market and is seeking a Sr. Product Manager, Therapeutics. This person will represent the marketing team in therapeutics to prepare for the product launch of DaxibotulinumtoxinA for Injection in a highly competitive space. The primary focus is on developing and leading the overall strategy, content, and tactics which will drive demand and build brand equity.

This role will help to ensure all key elements of the launch are properly planned and executed. This includes, but is not limited to, developing and implementing marketing and advertising initiatives, tracking key performance metrics, managing agency partners, developing and executing digital launch programs, and implementing physician education initiatives.

Essential Duties/Responsibilities

Develop and Execute Launch Planning

Collaborate with Vice President, Marketing to develop, manage and execute an integrated product launch strategy to achieve business goals.

Includes full market mix including digital, print, CME, patient programs, etc.

Develop a tactical plan that addresses the brand’s strategy and considers the patient journey, drivers & barriers, competition, SWOT, physician targeting and segmentation.

Prepare an overall market and competitive analysis which will include market research and engagement with physician thought leaders.

Ensure all commercial objectives associated with the product launch are achieved through tracking key performance indicators for major initiatives.

Read more:
https://www.revance.com/careers/job-listings/?p=job%2Fo5g1efwk

____________________________________________

BTW - I'm ALIVE! Just had a stent implanted in a major artery that was 90% blocked. Take care of yourselves, my friends.

Why did the stock burp yesterday? Good question.

Select any 5:

1. Shorts covering DEW to upcoming approval. Friday there were 11 large block trades. Funds, shorts are in this mix.

Currently 3.4M shorts -
https://shortsqueeze.com/?symbol=RVNC

2. FDA inspection took place. Always a leak here.

3. FLO FOUNDATION increased their count.

4. Investors finally realized the vast potential of DAXI.
In this regard, I had previously posted the following:

DAXI Impresses; Approaches FDA Approval
March 2, 2021
Lisette Hilton

Dermatology Times

Excerpts:
The investigational neuromodulator, evaluated in clinical trials as a treatment for glabellar lines and as a combined therapy for glabellar, dynamic forehead, and lateral canthal lines, is quickly nearing an approval by the FDA.

The long-awaited, longer-lasting neuromodulator drug candidate DaxibotulinumtoxinA for Injection (DAXI), a botulinum toxin type A formulated with a novel peptide excipient, may be nearing FDA approval.

Jeffrey S. Dover, MD, FRCPC, a phase 2 study investigator and a dermatologist at SkinCare Physicians in Chestnut Hill, Massachusetts. “I think this is yet more evidence that the Revance neuromodulator produces an impressive effect on lines of negative facial expression and lasts longer than any of the other neuromodulators approved by the FDA thus far,” said Dover.

Read more:
https://www.dermatologytimes.com/view/daxi-impresses-approaches-fda-approval

DAXI Impresses; Approaches FDA Approval
March 2, 2021
Lisette Hilton

Dermatology Times

Excerpts:
The investigational neuromodulator, evaluated in clinical trials as a treatment for glabellar lines and as a combined therapy for glabellar, dynamic forehead, and lateral canthal lines, is quickly nearing an approval by the FDA.

The long-awaited, longer-lasting neuromodulator drug candidate DaxibotulinumtoxinA for Injection (DAXI), a botulinum toxin type A formulated with a novel peptide excipient, may be nearing FDA approval.

Jeffrey S. Dover, MD, FRCPC, a phase 2 study investigator and a dermatologist at SkinCare Physicians in Chestnut Hill, Massachusetts. “I think this is yet more evidence that the Revance neuromodulator produces an impressive effect on lines of negative facial expression and lasts longer than any of the other neuromodulators approved by the FDA thus far,” said Dover.

Read more:
https://www.dermatologytimes.com/view/daxi-impresses-approaches-fda-approval

From the same article -

The agency is also studying the possibility of conducting “virtual inspections,” using video and other tools, an idea it has also considered for inspecting food. FDA is currently studying “remotely evaluating a facility by viewing live streaming video of operations and other live interactions designed to simulate as closely as possible what happens during an actual inspection,” an agency spokesperson said.

FDA did not give a timeline for completing its assessment or launching virtual inspections, which are already being used by drug regulators in United Kingdom, the European Union, Canada and Australia.

Read more:
https://www.politico.com/news/2021/03/02/fda-pandemic-drug-inspection-471979

Mostly new Web site layout which includes a PRESTIGE MARKET with DaxibotulinumtoxinA. IMHO - the FDA approval is forthcoming -

https://www.revance.com/

Mostly new Web site layout which includes a PRESTIGE MARKET with DaxibotulinumtoxinA. IMHO - the FDA approval is forthcoming -

https://www.revance.com/

Revance Therapeutics (NASDAQ:RVNC) PT Raised to $35.00 at HC Wainwright - March 1

Revance Therapeutics (NASDAQ:RVNC) had its price target boosted by equities researchers at HC Wainwright from $33.00 to $35.00 in a report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 32.03% from the stock’s current price.

https://www.americanbankingnews.com/2021/03/01/revance-therapeutics-nasdaqrvnc-pt-raised-to-35-00-at-hc-wainwright.html

What's UP, DOC?? Is GOLUM in the basement?

RVNC new Nashville mystical address -

1222 Demonbreun St

Demon!!

breun (comparative brèine)

stinking, fetid, putrid
filthy, loathsome, nasty, corrupt
bold, indelicate (as a female)
of a turbulent, boisterous disposition
clumsy
beastly, brutal

In contrast - FLO (no)WAY is melodic LOL

Dew - what's to prevent management from contracting with a FDA approved manufacturing facility for a year period? Then, switch to their own plant once inspected & approved. Is it because both facilities would require lengthy inspections for a new drug? TIA.

Unless, of course, RVNC feels approval (often implied in their career posts), is impending.

Your attention, please

New career post -

The Revance Aesthetics Product Manager/Sr. Product Manager will support the Sr. Director of Marketing in Aesthetics to prepare the brand for a product launch in the highly competitive aesthetics market. This role will help ensure critical elements of the marketing mix are skillfully planned and executed. The responsibilities include, but are not limited to, developing and implementing marketing and advertising initiatives, serving as a project manager, attending and planning meetings, managing agency partners, executing brand campaigns and other strategic imperatives, and working across functions to ensure launch readiness.

Develop and execute professional (i.e., healthcare professionals) marketing plans to prepare for launch and deliver differentiated value to our customers to help meet company goals.
Build and execute downstream marketing initiatives, including brand campaigns targeted at professionals.

Read more:
https://www.revance.com/careers/job-listings/?p=job%2FoKBHefw0

Revance to Participate in Upcoming Virtual Healthcare Conferences
February 24 2021 - 04:05PM

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, will participate in fireside chats at the Cowen 41st Annual Virtual Healthcare Conference on March 3, 2021 and at the Barclays Global Healthcare Conference on March 9, 2021.

https://finance.yahoo.com/news/revance-participate-upcoming-virtual-healthcare-210500334.html

From Twitter -

Needham All Daxi doses demonstrated a duration of at least 24 wks. $RVNC remains one of our top-ideas due to Daxi's mostly-derisked vast potential, and the co's M&A appeal. maintain our Buy rating and $45PT.

Cowen: $RVNC STRONG EARLY RHA PERFORMANCE NICELY LAYING THE GROUNDWORK FOR DAXI, Importantly, DAXI continued
to demonstrate differentiated durability up to 24 weeks, which could also – like the aesthetic market – alter the therapeutic treatment paradigm. TP=$55.

As I've stated several times on the RVNC Board - I feel the FDA inspection is a fait accompli - therefore, approval is forthcoming.

Proof:
We manufacture our primary drug candidate, DaxibotulinumtoxinA
for Injection. This neuromodulator is a proprietary formulation of
botulinum toxin A, deemed a Tier 1 Select Agent by the Centers for
Disease Control and Prevention (CDC). Thus, our research, development and manufacturing operations are highly regulated. Our operations are regularly inspected by the U.S. Food and Drug Administration (FDA),the U.S. Department of Homeland Security and the Centers for Disease Control and Prevention. Due to the nature of DaxibotulinumtoxinA, and the required regulatory oversight, there is a great deal of social and scientific responsibility on the company. We take that responsibility extremely seriously as evidenced by our policies, procedures, and operations. And the company is audited by local, state and federal agencies, and we have met or exceeded all safety and environmental standards on an annual basis to ensure proper safety measures exist.

https://www.revance.com/wp-content/uploads/RVNC-ESG-Report-2020_final.pdf. [p.3]

Levity at mid-day -

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2020 Results - Earnings Call Transcript

https://seekingalpha.com/article/4408087-revance-therapeutics-inc-rvnc-ceo-mark-foley-on-q4-2020-results-earnings-call-transcript